The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pharmacodynamics and gene expression analysis of patients with renal cell carcinoma treated with combination nivolumab and TPST-1120 in a phase I clinical trial (NCT03829436).
 
Bruno R. Bastos
Consulting or Advisory Role - AstraZeneca; AVEO; Bayer; Dendreon; Epizyme; Genzyme; Janssen Oncology; Lilly; Regeneron
Speakers' Bureau - Exelixis; Pfizer/Myovant; Sanofi/Regeneron; Seattle Genetics/Astellas
Research Funding - Actuate Therapeutics (Inst); Altor BioScience (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Nektar (Inst); Tempest Therapeutics (Inst); Tolero Pharmaceuticals (Inst); US Oncology (Inst)
 
Nathan Standifer
Employment - Tempest Therapeutics
Stock and Other Ownership Interests - Amgen; AstraZeneca; Tempest Therapeutics
 
Rohan Garje
Research Funding - Amgen (Inst); Endocyte/Advanced Accelerator Applications (Inst); Immunomedics (Inst); Pfizer (Inst); xencor (Inst)
 
Sam H. Whiting
Employment - Calithera Biosciences; Recludix Pharma (I); Seagen (I); Tempest Therapeutics
Leadership - Recludix Pharma (I); Tempest Therapeutics
Stock and Other Ownership Interests - Recludix Pharma (I); Tempest Therapeutics